Drugs that contain Cilastatin Sodium; Imipenem; Relebactam

1. List of Recarbrio drug patents

Can you believe RECARBRIO received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8487093 MSD MERCK CO β-lactamase inhibitors
Nov, 2029

(6 years from now)

Do you want to check out RECARBRIO patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 16, 2024
Generating Antibiotic Incentives Now (GAIN) Jul 16, 2029

NCE-1 date: 2028-07-16

Market Authorisation Date: 16 July, 2019

Treatment: Treatment of complicated intra-abdominal infections (ciai); Treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (habp/vabp); Treatment of complicated urina...

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

RECARBRIO family patents

4

United States

3

Japan

3

Lithuania

2

Spain

2

Hong Kong

2

Denmark

2

RS

2

Poland

2

China

2

Croatia

2

Korea, Republic of

2

Cyprus

2

Portugal

2

Ecuador

2

Netherlands

2

Slovenia

2

Hungary

2

European Union

1

Dominican Republic

1

Malaysia

1

Russia

1

Brazil

1

Canada

1

Ukraine

1

Morocco

1

Norway

1

ME

1

Nicaragua

1

Honduras

1

New Zealand

1

Israel

1

Mexico

1

Australia

1

Costa Rica

1

South Africa

1

Colombia

1

Luxembourg

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic